DYAZIDE
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYAZIDE is an oral capsule small-molecule NDA approved in 1965 by GSK. The specific indication and mechanism of action are not documented in available records. This is a legacy product with significant commercial and clinical history.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial team focus likely shifting to generic transition and brand value protection.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring for DYAZIDE roles; the LOE-approaching lifecycle suggests a contracting team focused on revenue management rather than growth. Career growth on this product is limited; professionals should evaluate exit timing or transition to pipeline assets.
Brand ManagerField Sales Representative
Worked on DYAZIDE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.